LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Search

TransMedics Group Inc

Closed

SectorHealthcare

67.79 -6.96

Overview

Share price change

24h

Current

Min

67.52

Max

69.01

Key metrics

By Trading Economics

Income

81M

105M

Sales

17M

161M

P/E

Sector Avg

20.524

49.8

Profit margin

65.551

Employees

898

EBITDA

-916K

32M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+92.81% upside

Dividends

By Dow Jones

Next Earnings

29 lip 2026

Market Stats

By TradingEconomics

Market Cap

-1.2B

3.4B

Previous open

74.75

Previous close

67.79

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

TransMedics Group Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 sie 2025, 19:15 UTC

Major Market Movers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Peer Comparison

Price change

TransMedics Group Inc Forecast

Price Target

By TipRanks

92.81% upside

12 Months Forecast

Average 130.8 USD  92.81%

High 175 USD

Low 85 USD

Based on 11 Wall Street analysts offering 12 month price targets forTransMedics Group Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

7

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

92.43 / 94.18Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat